Annual Current Liabilities
$1.68 M
-$1.73 M-50.63%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual total current liabilities is $1.68 million, with the most recent change of -$1.73 million (-50.63%) on March 1, 2024.
- During the last 3 years, GRCE annual current liabilities has risen by +$105.00 thousand (+6.65%).
- GRCE annual current liabilities is now -87.68% below its all-time high of $13.67 million, reached on March 1, 2019.
Performance
GRCE Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$2.67 M
+$74.00 K+2.85%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly total current liabilities is $2.67 million, with the most recent change of +$74.00 thousand (+2.85%) on September 1, 2024.
- Over the past year, GRCE quarterly current liabilities has increased by +$904.00 thousand (+51.07%).
- GRCE quarterly current liabilities is now -80.44% below its all-time high of $13.67 million, reached on March 1, 2019.
Performance
GRCE Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
GRCE Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -50.6% | +51.1% |
| 3 y3 years | +6.7% | -29.7% |
| 5 y5 years | -87.7% | -77.0% |
GRCE Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -50.6% | +6.7% | -29.7% | +91.4% |
| 5 y | 5-year | -87.7% | +6.7% | -75.6% | +91.4% |
| alltime | all time | -87.7% | +100.0% | -80.4% | +217.6% |
Grace Therapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.67 M(+2.8%) |
| Jun 2024 | - | $2.60 M(+54.4%) |
| Mar 2024 | $1.68 M(-50.6%) | $1.68 M(-4.9%) |
| Dec 2023 | - | $1.77 M(+26.7%) |
| Sep 2023 | - | $1.40 M(-28.9%) |
| Jun 2023 | - | $1.97 M(-42.4%) |
| Mar 2023 | $3.41 M(+4.6%) | $3.41 M(-0.6%) |
| Dec 2022 | - | $3.43 M(-9.8%) |
| Sep 2022 | - | $3.81 M(+2.6%) |
| Jun 2022 | - | $3.71 M(+13.7%) |
| Mar 2022 | $3.26 M(+106.5%) | $3.26 M(+12.5%) |
| Dec 2021 | - | $2.90 M(-35.3%) |
| Sep 2021 | - | $4.48 M(+90.9%) |
| Jun 2021 | - | $2.35 M(+48.5%) |
| Mar 2021 | $1.58 M(-78.6%) | $1.58 M(-29.8%) |
| Dec 2020 | - | $2.25 M(-40.1%) |
| Sep 2020 | - | $3.75 M(-37.3%) |
| Jun 2020 | - | $5.98 M(-19.1%) |
| Mar 2020 | $7.39 M(-45.9%) | $7.39 M(-32.5%) |
| Dec 2019 | - | $10.95 M(-5.7%) |
| Sep 2019 | - | $11.61 M(-12.8%) |
| Jun 2019 | - | $13.32 M(-2.5%) |
| Mar 2019 | $13.67 M(+163.6%) | $13.67 M(+34.4%) |
| Dec 2018 | - | $10.17 M(-0.3%) |
| Sep 2018 | - | $10.20 M(+30.9%) |
| Jun 2018 | - | $7.79 M(+50.3%) |
| Mar 2018 | $5.19 M(+223.5%) | $5.19 M(+30.5%) |
| Dec 2017 | - | $3.97 M(+45.4%) |
| Sep 2017 | - | $2.73 M(+76.3%) |
| Jun 2017 | - | $1.55 M |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | $1.60 M(+90.4%) | - |
| Nov 2016 | - | $1.31 M(+15.6%) |
| Aug 2016 | - | $1.13 M(-1.0%) |
| May 2016 | - | $1.14 M(+35.8%) |
| Feb 2016 | $842.00 K(-35.1%) | $842.00 K(-30.7%) |
| Nov 2015 | - | $1.22 M(+31.7%) |
| Aug 2015 | - | $923.20 K(-47.1%) |
| May 2015 | - | $1.75 M(+34.7%) |
| Feb 2015 | $1.30 M(+23.2%) | $1.30 M(-24.5%) |
| Nov 2014 | - | $1.72 M(-22.5%) |
| Aug 2014 | - | $2.22 M(+26.8%) |
| May 2014 | - | $1.75 M(+66.2%) |
| Feb 2014 | $1.05 M(-56.0%) | $1.05 M(-77.5%) |
| Nov 2013 | - | $4.69 M(+27.1%) |
| Aug 2013 | - | $3.69 M(+26.5%) |
| May 2013 | - | $2.92 M(+22.0%) |
| Feb 2013 | $2.39 M(+88.6%) | $2.39 M(+15.3%) |
| Nov 2012 | - | $2.07 M(+45.1%) |
| Aug 2012 | - | $1.43 M(-12.2%) |
| May 2012 | - | $1.63 M(+28.4%) |
| Feb 2012 | $1.27 M(-75.8%) | $1.27 M(+10.6%) |
| Nov 2011 | - | $1.15 M(-56.9%) |
| Aug 2011 | - | $2.66 M(+88.0%) |
| May 2011 | - | $1.41 M(-73.0%) |
| Feb 2011 | $5.24 M(+7.3%) | $5.24 M(+16.8%) |
| Nov 2010 | - | $4.49 M(-8.7%) |
| Aug 2010 | - | $4.91 M(+6.0%) |
| May 2010 | - | $4.64 M(-5.1%) |
| Feb 2010 | $4.88 M | $4.88 M(+13.1%) |
| Nov 2009 | - | $4.32 M |
FAQ
- What is Grace Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Grace Therapeutics?
- What is Grace Therapeutics annual current liabilities year-on-year change?
- What is Grace Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Grace Therapeutics?
- What is Grace Therapeutics quarterly current liabilities year-on-year change?
What is Grace Therapeutics annual total current liabilities?
The current annual current liabilities of GRCE is $1.68 M
What is the all time high annual current liabilities for Grace Therapeutics?
Grace Therapeutics all-time high annual total current liabilities is $13.67 M
What is Grace Therapeutics annual current liabilities year-on-year change?
Over the past year, GRCE annual total current liabilities has changed by -$1.73 M (-50.63%)
What is Grace Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of GRCE is $2.67 M
What is the all time high quarterly current liabilities for Grace Therapeutics?
Grace Therapeutics all-time high quarterly total current liabilities is $13.67 M
What is Grace Therapeutics quarterly current liabilities year-on-year change?
Over the past year, GRCE quarterly total current liabilities has changed by +$904.00 K (+51.07%)